L
Laure Moutouh-de Parseval
Researcher at Novartis
Publications - 9
Citations - 1277
Laure Moutouh-de Parseval is an academic researcher from Novartis. The author has contributed to research in topics: Vemurafenib & Binimetinib. The author has an hindex of 6, co-authored 8 publications receiving 855 citations.
Papers
More filters
Journal ArticleDOI
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer,Paolo A. Ascierto,Helen Gogas,Ana Arance,Mario Mandalà,Gabriella Liszkay,Claus Garbe,Dirk Schadendorf,Ivana Krajsová,Ralf Gutzmer,Vanna Chiarion-Sileni,Caroline Dutriaux,Jan Willem de Groot,Naoya Yamazaki,Carmen Loquai,Laure Moutouh-de Parseval,Michael D Pickard,Victor Sandor,Caroline Robert,Keith T. Flaherty +19 more
TL;DR: This study investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenIB in patients with advanced BRAFV600-mutant melanoma, and showed favourable efficacy compared with vemurAFenib.
Journal ArticleDOI
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer,Paolo A. Ascierto,Helen Gogas,Ana Arance,Mario Mandalà,Gabriella Liszkay,Claus Garbe,Dirk Schadendorf,Ivana Krajsová,Ralf Gutzmer,Vanna Chiarion Sileni,Caroline Dutriaux,Jan Willem de Groot,Naoya Yamazaki,Carmen Loquai,Laure Moutouh-de Parseval,Michael D Pickard,Victor Sandor,Caroline Robert,Keith T. Flaherty +19 more
TL;DR: The prespecified interim overall survival analysis of the COLUMBUS trial improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma and provided clinically meaningful efficacy as shown by overall survival.
Journal ArticleDOI
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Jean Pierre Delord,Caroline Robert,Marta Nyakas,Grant A. McArthur,Ragini Kudchakar,Amit Mahipal,Yasuhide Yamada,Ryan J. Sullivan,Ana Arance,Richard F. Kefford,Richard F. Kefford,Matteo S. Carlino,Manuel Hidalgo,Carlos Gomez-Roca,Daniela Michel,Abdelkader Seroutou,Vassilios Aslanis,Giordano Caponigro,Darrin Stuart,Laure Moutouh-de Parseval,Tim Demuth,Reinhard Dummer +21 more
TL;DR: Once-daily dosing of single-agent encorafenib had a distinct tolerability profile and showed varying antitumor activity across BRAFi-pretreated and BRA Fi-naïve patients with advanced/metastatic melanoma.
Journal ArticleDOI
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice
Steffen E. Meiler,Marlene F. Wade,Ferdane Kutlar,Shobha Yerigenahally,Yongjun Xue,Laure Moutouh-de Parseval,Laura G. Corral,Paul Swerdlow,Abdullah Kutlar +8 more
TL;DR: Pomalidomide has been shown to induce fetal hemoglobin (HbF) expression in a transgenic mouse model of sickle cell disease and β-thalassemia.
Journal ArticleDOI
Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results
Richard F. Kefford,Ryan J. Sullivan,Wilson H. Miller,Elena Elez,Daniel Tan,Kevin B. Kim,Georgina V. Long,Keith T. Flaherty,David Tai,Simone Stutvoet,Heiko Maacke,Matt Whiley,Laure Moutouh-de Parseval,Josep Tabernero +13 more
TL;DR: In this article, an open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, a oral MEK1/2 inhibitor, was conducted in patients with BRAF V600-dependent advanced solid tumors.